MX2009007914A - Composiciones farmaceuticas novedosas. - Google Patents
Composiciones farmaceuticas novedosas.Info
- Publication number
- MX2009007914A MX2009007914A MX2009007914A MX2009007914A MX2009007914A MX 2009007914 A MX2009007914 A MX 2009007914A MX 2009007914 A MX2009007914 A MX 2009007914A MX 2009007914 A MX2009007914 A MX 2009007914A MX 2009007914 A MX2009007914 A MX 2009007914A
- Authority
- MX
- Mexico
- Prior art keywords
- 3alkyl
- ring
- nitrogen
- hydrogen
- haloc1
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 5
- 229910052739 hydrogen Inorganic materials 0.000 abstract 3
- 239000001257 hydrogen Substances 0.000 abstract 3
- 229910052757 nitrogen Inorganic materials 0.000 abstract 3
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 2
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 abstract 2
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 2
- -1 haloC1-3alkyl Chemical group 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 150000002367 halogens Chemical class 0.000 abstract 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 208000019022 Mood disease Diseases 0.000 abstract 1
- 102000002002 Neurokinin-1 Receptors Human genes 0.000 abstract 1
- 108010040718 Neurokinin-1 Receptors Proteins 0.000 abstract 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 1
- 239000005864 Sulphur Substances 0.000 abstract 1
- 125000006615 aromatic heterocyclic group Chemical group 0.000 abstract 1
- 125000004429 atom Chemical group 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 206010015037 epilepsy Diseases 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 150000002431 hydrogen Chemical class 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract 1
- 125000004430 oxygen atom Chemical group O* 0.000 abstract 1
- 239000002464 receptor antagonist Substances 0.000 abstract 1
- 229940044551 receptor antagonist Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229920006395 saturated elastomer Polymers 0.000 abstract 1
- 229940125794 sodium channel blocker Drugs 0.000 abstract 1
- 239000003195 sodium channel blocking agent Substances 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Anesthesiology (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyrrole Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La presente invención se refiere a composiciones farmacéuticas que comprenden un antagonista del receptor NK1 y un compuesto bloqueador de los canales de sodio de fórmula (I): (ver fórmula I) en donde: R1 Y R2 son independientemente hidrógeno, alquilo de C1-6 o cicloalquilo de C3-6-alquilo de C1-6, o R1 y R2, junto con el nitrógeno al cual están unidos, pueden formar un anillo saturado de 3, 4, 5 o 6 miembros no sustituido; q es 1 o 2; R3 y R4 son hidrógeno; o cuando q es 1, R3 y R4, junto con los átomos de interconexión, pueden formar un anillo de ciclopropano; X es carbono o nitrógeno; n es 0, 1 o 2, en donde cuando está presente cada R5 se selecciona independientemente de la lista que consiste de alquilo de C1-3, halógeno, ciano, haloalquilo de C1-3, hidroxi, alcoxi de C1-3 y haloalcoxi de C1-3 y R6 o R7 es -O-R8 o -OCH2R8, en donde el otro R6 o R7 es hidrógeno o R5 y en donde R8 es un anillo de fenilo o un anillo heterocíclico aromático de 5 o 6 miembros (que contiene independientemente uno o más átomos de nitrógeno, azufre u oxígeno), en donde el anillo de fenilo o el anillo heterocíclico es opcionalmente sustituido por uno más grupos seleccionados independientemente de la lista que consiste de alquilo de C1-3, halógeno, ciano, haloalquilo de C1-3, hidroxi, alcoxi de C1-3, y haloalcoxi de C1-3; o una sal o solvato farmacéuticamente aceptable de la misma, como una preparación combinada para administración simultánea o secuencial, y al uso de dichas composiciones en el tratamiento de ciertos trastornos, que incluyen epilepsia y trastornos del humor.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0701365.9A GB0701365D0 (en) | 2007-01-24 | 2007-01-24 | Novel pharmaceutical compositions |
| PCT/EP2008/050623 WO2008090116A1 (en) | 2007-01-24 | 2008-01-21 | Novel pharmaceutical compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2009007914A true MX2009007914A (es) | 2009-07-31 |
Family
ID=37872716
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2009007914A MX2009007914A (es) | 2007-01-24 | 2008-01-21 | Composiciones farmaceuticas novedosas. |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20090318530A1 (es) |
| EP (1) | EP2117535B1 (es) |
| JP (1) | JP2010516733A (es) |
| KR (1) | KR20090122933A (es) |
| CN (1) | CN101959513A (es) |
| AT (1) | ATE530182T1 (es) |
| AU (1) | AU2008208919A1 (es) |
| BR (1) | BRPI0808657A2 (es) |
| CA (1) | CA2676175A1 (es) |
| EA (1) | EA200970705A1 (es) |
| ES (1) | ES2374025T3 (es) |
| GB (1) | GB0701365D0 (es) |
| MX (1) | MX2009007914A (es) |
| WO (1) | WO2008090116A1 (es) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200728258A (en) | 2005-10-10 | 2007-08-01 | Glaxo Group Ltd | Novel compounds |
| TW200730494A (en) | 2005-10-10 | 2007-08-16 | Glaxo Group Ltd | Novel compounds |
| JP5139307B2 (ja) | 2005-10-10 | 2013-02-06 | グラクソ グループ リミテッド | ナトリウムチャネルモジュレーターとしてのプロリンアミド誘導体 |
| WO2011015537A1 (en) * | 2009-08-05 | 2011-02-10 | Glaxo Group Limited | Co-therapy for the treatment of epilepsy and related disorders |
| EP2477964B1 (en) | 2009-09-14 | 2015-02-11 | Convergence Pharmaceuticals Limited | Process for preparing alpha-carboxamide derivatives |
| CN102188424B (zh) * | 2011-03-23 | 2013-03-27 | 浙江理工大学 | Sr140333的抗血癌作用 |
| GB201122113D0 (en) | 2011-12-22 | 2012-02-01 | Convergence Pharmaceuticals | Novel compounds |
| GB201209015D0 (en) | 2012-05-22 | 2012-07-04 | Convergence Pharmaceuticals | Novel compounds |
| WO2016102967A1 (en) | 2014-12-23 | 2016-06-30 | Convergence Pharmaceuticals Limited | Process for preparing alpha-carboxamide pyrrolidine derivatives |
| CN104865336B (zh) * | 2015-06-09 | 2017-04-12 | 成都百裕制药股份有限公司 | 高效液相色谱检测阿瑞匹坦中有关物质的方法 |
| MX2020003811A (es) | 2017-10-05 | 2021-01-15 | Biogen Inc | Proceso para preparar derivados de alfa-carboxamida pirrolidina. |
| SG11202002707VA (en) | 2017-10-10 | 2020-04-29 | Biogen Inc | Process for preparing spiro derivatives |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL116249A (en) * | 1994-12-12 | 2003-07-06 | Pfizer | Nk-1 receptor antagonists for the treatment of neuronal damage and stroke |
| RU2156250C2 (ru) * | 1995-04-24 | 2000-09-20 | Новартис Аг | Производные хромона, способ их получения и фармацевтическая композиция |
| TW200728258A (en) * | 2005-10-10 | 2007-08-01 | Glaxo Group Ltd | Novel compounds |
| TW200730494A (en) * | 2005-10-10 | 2007-08-16 | Glaxo Group Ltd | Novel compounds |
| JP5139307B2 (ja) * | 2005-10-10 | 2013-02-06 | グラクソ グループ リミテッド | ナトリウムチャネルモジュレーターとしてのプロリンアミド誘導体 |
-
2007
- 2007-01-24 GB GBGB0701365.9A patent/GB0701365D0/en not_active Ceased
-
2008
- 2008-01-21 CA CA002676175A patent/CA2676175A1/en not_active Abandoned
- 2008-01-21 ES ES08708027T patent/ES2374025T3/es active Active
- 2008-01-21 KR KR1020097017501A patent/KR20090122933A/ko not_active Withdrawn
- 2008-01-21 MX MX2009007914A patent/MX2009007914A/es unknown
- 2008-01-21 WO PCT/EP2008/050623 patent/WO2008090116A1/en not_active Ceased
- 2008-01-21 JP JP2009546730A patent/JP2010516733A/ja active Pending
- 2008-01-21 EA EA200970705A patent/EA200970705A1/ru unknown
- 2008-01-21 AT AT08708027T patent/ATE530182T1/de not_active IP Right Cessation
- 2008-01-21 CN CN2008800097508A patent/CN101959513A/zh active Pending
- 2008-01-21 EP EP08708027A patent/EP2117535B1/en not_active Not-in-force
- 2008-01-21 US US12/524,422 patent/US20090318530A1/en not_active Abandoned
- 2008-01-21 AU AU2008208919A patent/AU2008208919A1/en not_active Abandoned
- 2008-01-21 BR BRPI0808657-5A patent/BRPI0808657A2/pt not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| BRPI0808657A2 (pt) | 2014-08-19 |
| AU2008208919A1 (en) | 2008-07-31 |
| CA2676175A1 (en) | 2008-07-31 |
| ES2374025T3 (es) | 2012-02-13 |
| EP2117535A1 (en) | 2009-11-18 |
| EA200970705A1 (ru) | 2010-02-26 |
| EP2117535B1 (en) | 2011-10-26 |
| WO2008090116A1 (en) | 2008-07-31 |
| ATE530182T1 (de) | 2011-11-15 |
| GB0701365D0 (en) | 2007-03-07 |
| JP2010516733A (ja) | 2010-05-20 |
| CN101959513A (zh) | 2011-01-26 |
| US20090318530A1 (en) | 2009-12-24 |
| KR20090122933A (ko) | 2009-12-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2009007914A (es) | Composiciones farmaceuticas novedosas. | |
| GB0701366D0 (en) | Novel pharmaceutical compositions | |
| TWI262917B (en) | 2-Furancarboxylic hydrazides and pharmaceutical compositions containing the same | |
| GB0226724D0 (en) | Therapeutic agents | |
| MX2010001189A (es) | Derivados de naftiridina como modulares del canal de potasio. | |
| TW200716528A (en) | Cyclopropanecarboxamide derivatives | |
| EP1361220A4 (en) | CYCLIC COMPOUNDS WITH THROMBOPOIETIN RECEPTAGONISM | |
| EA200700099A1 (ru) | Производные пиридина | |
| HUP0302960A2 (hu) | Kemokinreceptorhoz kötődő heterociklusos vegyületek, alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények | |
| TW200726765A (en) | Triazolopyridine cannabinoid receptor 1 antagonists | |
| ZA200706354B (en) | Substituted thiophene derivatives as glucagon receptor antagonists, preparation and therapeutic uses | |
| TN2009000180A1 (en) | NOVEL 1,4-BENZOTHIEPIN-l,1-DIOXIDE DERIVATIVES WHICH ARE SUBSTITUTED WITH BENZYL GROUPS, METHOD FOR PRODUCING DRUGS CONTAINING SAID COMPOUNDS AND USE THEREOF | |
| MX2009004662A (es) | Compuestos de pirazolina como antagonistas receptores de mineralocorticoides. | |
| DK1786790T3 (da) | Oxazolderivater som histamin H3 receptorstoffer, fremstilling og terapeutiske anvendelser | |
| MX2009013581A (es) | Derivados de 4-(n-azacicloalquil)anilidas como moduladores del canal de potasio. | |
| MX2018006225A (es) | Composicion farmaceutica para el tratamiento o prevencion de esteatohepatitis no alcoholica (nash). | |
| PH12012500867A1 (en) | Ethynyl derivatives | |
| TW200612920A (en) | Novel imidazolidine derivatives | |
| MX2009005242A (es) | Derivados de 3-(hetero)arilisoquinolinamida sustituida en posición 5, 6 o 7 y uso terapeutico del mismo. | |
| WO2021058754A8 (en) | Pharmaceutical compounds | |
| PH12022550860A1 (en) | 5-oxa-2-azaspiro[3.4]octane derivatives as m4 agonists | |
| JOP20220082A1 (ar) | مشتقات 2- آزا سبيرو [3.4] أوكتان كناهضات لـ m4 | |
| EA201071259A1 (ru) | Спиро(пиперидин-4,2-пирролидин)-1-(3,5-трифторметилфенил)метилкарбоксамиды в качестве антагонистов рецептора nk1 тахикинина | |
| PL1732902T3 (pl) | Pochodne nukleozydów i ich terapeutyczne zastosowanie | |
| SE0400440D0 (sv) | Novel Cinnamic Amides |